The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Open accessAbstract
Learning Objectives: After completing this course, the reader should be able to: Describe the subtypes of Toll-like receptor 7 and 8 agonists and their effect on the different components of the antitumor immune response.Argue why they are used as stand-alone immunotherapeutic agents.Evaluate their potential to improve current approaches of active and passive immunotherapy. CME This article is available for continuing medical education credit at CME.TheOncologist.com The importance of Toll-like receptors (TLRs) in stimulating innate and adaptive immunity is now well established. In view of this, TLR ligands have become interesting targets to use as stand-alone immunotherapeutics or vaccine adjuvants for cancer treatment. TLR7 and TLR8 were found to be closely related, sharing their intracellular endosomal location, as well as their ligands. In this review, we describe the agonists of TLR7 and TLR8 that are known so far, as well as their contribution to antitumor responses by affecting immune cells, tumor cells, and the tumor microenvironment. The major benefit of TLR7/8 agonists as immune response enhancers is their simultaneous stimulation of several cell types, resulting in a mix of activated immune cells, cytokines and chemokines at the tumor site. We discuss the studies that used TLR7/8 agonists as stand-alone immunotherapeutics or cancer vaccine adjuvants, as well as the potential of TLR7/8 ligands to enhance antitumor responses in passive immunotherapy approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586
The role of type I interferons in TLR responses
Noppert, S. J., Fitzgerald, K. A., & Hertzog, P. J. (2007) · Immunology & Cell Biology · doi:10.1038/sj.icb.7100099 · Cited by 135
Van den Bosch, G. A., Ponsaerts, P., Nijs, G., Lenjou, M., Vanham, G., Van Bockstaele, D. R., Berneman, Z. N., & Van Tendeloo, V. F. I. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02733.x · Cited by 36
Self-citation
Cited by
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
Self-citationThe Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M., & Sibilia, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61034 · Cited by 294
Recent clinical trends in Toll‐like receptor targeting therapeutics
Anwar, M. A., Shah, M., Kim, J., & Choi, S. (2019) · Medicinal Research Reviews · doi:10.1002/med.21553 · Cited by 275
mRNA as gene therapeutic: How to control protein expression
Tavernier, G., Andries, O., Demeester, J., Sanders, N. N., De Smedt, S. C., & Rejman, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.020 · Cited by 232
Metadata
- Authors
- Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N., & Van Tendeloo, V. F. I.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-01
- Volume
- 13
- Issue
- 8
- Pages
- 859-875
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2129053095
- Cited by
- 215
- References
- 6
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy. https://app.cochat.ai/papers/10.1634/theoncologist.2008-0097
- The paper
- Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N., & Van Tendeloo, V. F. I. (2008). The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy. The Oncologist. https://doi.org/10.1634/theoncologist.2008-0097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.